Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.37 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.37 |
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10143054 | 0.80 | POLRMT (0.49) | POLRMTP2RX3P2RX1P2RX2P2RX4 | |
| SCHEMBL23047623 | 0.79 | POLRMT (0.50) | POLRMTP2RX3P2RX1P2RX2P2RY2 | |
| SCHEMBL4967938 | 0.78 | POLRMT (0.48) | POLRMTP2RX3P2RX1P2RX2P2RX4 | |
| SCHEMBL23047655 | 0.78 | POLRMT (0.49) | POLRMTP2RX3P2RX1P2RX2P2RY2 | |
| SCHEMBL10120078 | 0.78 | POLRMT (0.51) | POLRMTP2RX3P2RX1P2RX2P2RY2 | |
| SCHEMBL24074599 | 0.78 | POLRMT (0.49) | POLRMTP2RX3P2RX1P2RX2P2RX4 | |
| SCHEMBL10141879 | 0.78 | POLRMT (0.47) | POLRMTP2RX3P2RX1P2RX2P2RX4 | |
| SCHEMBL24058168 | 0.77 | POLRMT (0.48) | POLRMTP2RX3P2RX1P2RX2P2RY2 | |
| SCHEMBL22393102 | 0.77 | POLRMT (0.48) | POLRMTP2RX3P2RX1P2RX2P2RY2 | |
| SCHEMBL882157 | 0.77 | POLRMT (0.45) | POLRMTP2RX3P2RX1P2RX2P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017184668-A1 | METHODS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20150329583-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | ENERGY, UNITED STATES DEPARTMENT OF | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329583-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | RAD18, MVD, USP18 | POLRMT 1342/4885P2RX3 4246/4885P2RX1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.